Inflammatory Biomarkers in Stable Atherosclerosis

American Journal of Cardiology

Volumn 98, Issue 11 SUPPL., 2006, Pages S2-

  Kinlay, Scott ^a,b,c   Egido, Jesus ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FAS LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CULTURE; CLINICAL PRACTICE; CYTOTOXICITY; DISEASE COURSE; HEART DEATH; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

EID: 33751181868     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.014     Document Type: Article

References (58)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
2. Burke A.P., Kolodgie F.D., Farb A., Weber D.K., Malcom G.T., Smialek J., and Virmani R. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
3. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94 (1996) 2013-2020
4. Kinlay S., and Selwyn A.P. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 91 (2003) 9B-13B
5. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
6. Biasucci L.M., Vitelli A., Liuzzo G., Altamura S., Caligiuri G., Monaco C., Rebuzzi A.G., Ciliberto G., and Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation 94 (1996) 874-877
7. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., and Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417-424
8. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
9. Woollard K.J., Phillips D.C., and Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 130 (2002) 256-262
10. Han K.H., Hong K.H., Park J.H., Ko J., Kang D.H., Choi K.J., Hong M.K., Park S.W., and Park S.J. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109 (2004) 2566-2571
11. Banka C.L., Yuan T., de Beer M.C., Kindy M., Curtiss L.K., and de Beer F.C. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36 (1995) 1058-1065
12. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
13. Reynolds G.D., and Vance R.P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 111 (1987) 265-269
14. Zhang Y.X., Cliff W.J., Schoefl G.I., and Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 145 (1999) 375-379
15. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
16. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
17. Albert C.M., Ma J., Rifai N., Stampfer M.J., and Ridker P.M. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105 (2002) 2595-2599
18. Ray K.K., Cannon C.P., and Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials?. Am J Cardiol 98 suppl (2006) 18P-25P
19. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
20. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
21. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., and Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
22. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., and Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
23. van Wissen S., Trip M.D., Smilde T.J., de Graaf J., Stalenhoef A.F., and Kastelein J.J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165 (2002) 361-366
24. Kinlay S., Schwartz G.G., Olsson A.G., Rifai N., Leslie S.J., Sasiela W.J., Szarek M., Libby P., Ganz P., and Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 (2003) 1560-1566
25. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
26. Kinlay S., Timms T., Clark M., Karam C., Bilodeau T., Ridker P.M., Rifai N., Carlson W., Lloyd-Jones D.M., Johnstone M., et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 89 (2002) 1205-1207
27. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 (2002) 1235-1242
28. Kinlay S., Selwyn A.P., Libby P., and Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol 32 suppl 3 (1998) S62-S66
29. Rohde L.E., Lee R.T., Rivero J., Jamacochian M., Arroyo L.H., Briggs W., Rifai N., Libby P., Creager M.A., and Ridker P.M. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 18 (1998) 1765-1770
30. Kondo K., Kitagawa K., Nagai Y., Yamagami H., Hashimoto H., Hougaku H., and Hori M. Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression. Atherosclerosis 179 (2005) 155-160
31. Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto Jr. A.M., and Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
32. Luc G., Arveiler D., Evans A., Amouyel P., Ferrieres J., Bard J.M., Elkhalil L., Fruchart J.C., Ducimetiere P., and Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Group. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 170 (2003) 169-176
33. Malik I., Danesh J., Whincup P., Bhatia V., Papacosta O., Walker M., Lennon L., Thomson A., and Haskard D. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-976
34. Ascer E., Bertolami M.C., Venturinelli M.L., Buccheri V., Souza J., Nicolau J.C., Ramires J.A., and Serrano Jr. C.V. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177 (2004) 161-166
35. Nawawi H., Osman N.S., Annuar R., Khalid B.A., and Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 169 (2003) 283-291
36. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
37. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., Sarkioja T., Yoshimura T., Leonard E.J., Witztum J.L., and Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 88 (1991) 5252-5256
38. Egashira K., Zhao Q., Kataoka C., Ohtani K., Usui M., Charo I.F., Nishida K., Inoue S., Katoh M., Ichiki T., and Takeshita A. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90 (2002) 1167-1172
39. Koyanagi M., Egashira K., Kitamoto S., Ni W., Shimokawa H., Takeya M., Yoshimura T., and Takeshita A. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 102 (2000) 2243-2248
40. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
41. Hoogeveen R.C., Morrison A., Boerwinkle E., Miles J.S., Rhodes C.E., Sharrett A.R., and Ballantyne C.M. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 183 (2005) 301-307
42. Cipollone F., Marini M., Fazia M., Pini B., Iezzi A., Reale M., Paloscia L., Materazzo G., D'Annunzio E., Conti P., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
43. Deo R., Khera A., McGuire D.K., Murphy S.A., Meo Neto Jde P., Morrow D.A., and de Lemos J.A. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44 (2004) 1812-1818
44. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
45. Re F., Sironi M., Muzio M., Matteucci C., Introna M., Orlando S., Penton-Rol G., Dower S.K., Sims J.E., Colotta F., and Mantovani A. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J Exp Med 183 (1996) 1841-1850
46. Ferroni P., Basili S., Vieri M., Martini F., Labbadia G., Bellomo A., Gazzaniga P.P., Cordova C., and Alessandri C. Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis 29 (1999) 277-285
47. Ferroni P., Martini F., Cardarello C.M., Gazzaniga P.P., Davi G., and Basili S. Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation 108 (2003) 1673-1675
48. Geng Y.J. Molecular signal transduction in vascular cell apoptosis. Cell Res 11 (2001) 253-264
49. Geng Y.J., Henderson L.E., Levesque E.B., Muszynski M., and Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17 (1997) 2200-2208
50. Nishigaki K., Minatoguchi S., Seishima M., Asano K., Noda T., Yasuda N., Sano H., Kumada H., Takemura M., Noma A., et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29 (1997) 1214-1220
51. Troyanov S., Hebert M.J., Masse M., Vigneault N., Sirois I., and Madore F. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41 (2003) 1043-1051
52. Meier P., and Blanc E. Plasma level of soluble Fas is an independent marker of cardiovascular disease in ESRD patients. Kidney Int 64 (2003) 1532-1533
53. Blanco-Colio L.M., Munoz-Garcia B., Martin-Ventura J.L., Lorz C., Diaz C., Hernandez G., and Egido J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 108 (2003) 1506-1513
54. Blanco-Colio L.M., Martin-Ventura J.L., de Teresa E., Farsang C., Gaw A., Gensini G.F., Langer A., Leiter A., Martineau P., and Egido J. Increased soluble plasma concentrations in subjects at high cardiovascular risk. Atorvastatin on Inflammatory Markers (AIM) study: a sub-study of ACTFAST [abstract]. Circulation 112 suppl II (2005) II-804
55. Blanco-Colio L.M., Martin-Ventura J.L., Sol J.M., Diaz C., Hernandez G., and Egido J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 43 (2004) 1188-1194
56. Ridker P.M., and JUPITER [Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin] Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
57. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto Jr. A.M., and Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
58. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511